Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

Original publication

DOI

10.1038/nrcardio.2012.26

Type

Journal article

Journal

Nat Rev Cardiol

Publication Date

28/02/2012

Volume

9

Pages

262 - 263

Keywords

Aspirin, Cardiovascular Diseases, Cyclooxygenase Inhibitors, Humans, Primary Prevention, Risk Factors